Searched for
REVLIMID PRICING PRESSURE
Strait of Hormuz is now India's biggest market risk, says Ashi AnandIndian markets await clarity on Strait of Hormuz shipping. Ashi Anand of IME Capital suggests a defensive market approach. Oil prices near ...18 May, 2026, 11.56 AM IST- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...04 May, 2026, 06.00 AM IST
- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautiousDr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...24 Apr, 2026, 10.35 AM IST
- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...12 Apr, 2026, 08.51 AM IST
- Q3 results today: Eternal among 59 companies to report earnings on WednesdayIndian markets brace for a busy earnings day with 59 companies reporting Q3 results. Investors are keenly watching Eternal's expected stron...21 Jan, 2026, 07.56 AM IST
- Dr Reddy's Q3 preview: PAT may fall 22% YoY as US pressure to weigh on earningsDr Reddy's Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to...20 Jan, 2026, 12.46 PM IST
- Dr Reddy’s Q2 Preview: PAT may grow up to 11–18% YoY; revenue seen steady despite pricing pressure in USDr Reddy’s Laboratories is expected to post steady September-quarter earnings with 10–14% revenue growth led by India and Europe, though US...23 Oct, 2025, 03.12 PM IST
- Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive perf...13 Oct, 2025, 05.55 AM IST
- Drug companies set for improved revenue growth in June quarter amid US market challengesIndian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...22 Jul, 2025, 06.12 AM IST
- Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...04 Jul, 2025, 06.11 AM IST
- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...15 Apr, 2025, 09.22 AM IST
- Capacity push and new drugs critical for Aurobindo's healthA delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug appli...20 Mar, 2025, 06.00 AM IST
- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...26 Oct, 2023, 04.36 PM IST
- Sun facing some clouds is still a buy for analystsShares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% fro...30 May, 2023, 06.40 AM IST
- Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in USRevlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...09 Aug, 2022, 07.40 PM IST
- Dr Reddy’s Labs net profit doubles in Q1: What should investors do?Share of the pharma major fell about 4 per cent in the first one hour of the trade on Friday. Experts see concerns over the US business, as...29 Jul, 2022, 11.15 AM IST
- Sell NATCO Pharma, target price Rs 534: GeojitIf the coronavirus situation further worsens, NATCO may face a supply constraints of raw materials.16 Mar, 2020, 04.36 PM IST
Load More
